Prophase labs announces financial results for the year ended december 31, 2023 and significant progress in its strategic initiatives

Nebula genomics secures major international b2b deal – additional significant b2b deals in final stages ahead of schedule, pharmaloz manufacturing accelerates capacity expansion – set for rapid revenue and profit growth completes full transition and right sized operation in q4 from clinical lab to cutting edge genomics lab company to hold a conference call friday march 15, 2024, at 11:00 am et garden city, ny, march 15, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase” or the “company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended december 31, 2023. the end of 2023 marked a period of significant capacity expansion and growth for pharmaloz manufacturing inc. (pmi) as well as a pivotal transformation for the company, transitioning from a clinical laboratory framework to a leader in whole genome sequencing.
PRPH Ratings Summary
PRPH Quant Ranking